Erasca: Strong Data Overshadowed By A Patient Death And A Patent Fight [Seeking Alpha]
Erasca, Inc. (ERAS)
Company Research
Source: Seeking Alpha
Recent Phase 1 data for ERAS-0015 demonstrated strong target engagement and favorable unconfirmed response rates, but a Grade 5 pneumonitis event and IP risk triggered a sharp sell-off. Despite the safety signal, ERAS-0015's efficacy and tolerability profiles appear differentiated, with most responders remaining on treatment and a robust cash runway into 2028. I recommend a Hold rating on ERAS, balancing promising early data against binary event risk, competition, IP overhang, and persistent volatility. Dragos Condrea/iStock via Getty Images Overview Erasca ( ERAS ) is a perfect example of both the alpha and volatility that are inherent in biotechnology investing. Its stock was trading in the low single digits to begin the year before reaching This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Erasca stock sinks 50% after patient death in drug trial [Yahoo! Finance]Yahoo! Finance
- Patient Death Drags Erasca (ERAS) Shares by 48% [Yahoo! Finance]Yahoo! Finance
- Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial [Yahoo! Finance]Yahoo! Finance
- Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data [Yahoo! Finance]Yahoo! Finance
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 4/28/26 - Form ARS
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form DEF
- ERAS's page on the SEC website